PolyPeptide Group AG (PLYGF)
45.50
0.00 (0.00%)
USD |
OTCM |
May 11, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.502B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -- |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 3.399 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1952 and is headquartered in Baar, Switzerland. |
| URL | http://www.polypeptide.com |
| Investor Relations URL | N/A |
| HQ State/Province | Zug |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Aug. 13, 2026 |
| Last Earnings Release | Mar. 12, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 28, 2022 |
Profile
| PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1952 and is headquartered in Baar, Switzerland. |
| URL | http://www.polypeptide.com |
| Investor Relations URL | N/A |
| HQ State/Province | Zug |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Aug. 13, 2026 |
| Last Earnings Release | Mar. 12, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 28, 2022 |